{"generic":"Aspirin\/Butalbital\/Caffeine","drugs":["Aspirin\/Butalbital\/Caffeine","Fiorinal","Fortabs","Laniroif"],"mono":{"0":{"id":"20y9s0","title":"Generic Names","mono":"Aspirin\/Butalbital\/Caffeine"},"1":{"id":"20y9s1","title":"Dosing and Indications","sub":{"0":{"id":"20y9s1b4","title":"Adult Dosing","mono":"<b>Tension-type headache:<\/b> 1 to 2 tablets or capsules every 4 hours, max 6 tablets or capsules per day "},"1":{"id":"20y9s1b5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients"},"3":{"id":"20y9s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Tension-type headache<br\/>"}}},"3":{"id":"20y9s3","title":"Contraindications\/Warnings","sub":[{"id":"20y9s3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity or intolerance to aspirin, caffeine, or butalbital<\/li><li>hemorrhagic diathesis (eg, hemophilia, hypoprothrombinemia, von Willebrand's disease, thrombocytopenias, thrombasthenia, hereditary platelet dysfunction, severe vitamin K deficiency, severe liver damage)<\/li><li>peptic ulcer or other serious gastrointestinal lesions; significant bleeding may occur<\/li><li>porphyria<\/li><li>syndrome of nasal polyps, angioedema and bronchospastic reactivity to aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)<\/li><\/ul>"},{"id":"20y9s3b10","title":"Precautions","mono":"<ul><li>allergic reactions, severe; including anaphylactic shock may occur even without history of allergy; increased risk in patients with known allergies, nasal polyps, or asthma<\/li><li>bleeding or coagulation disorders, preexisting; significant bleeding may occur, especially in patients receiving concomitant anticoagulation therapy<\/li><li>children, including teenagers, with chicken pox or influenza; risk of Reye's syndrome<\/li><li>extended duration of use; not recommended due to abuse potential<\/li><li>preoperative administration; may prolong bleeding time<\/li><li>acute abdominal conditions<\/li><li>Addison's disease<\/li><li>concomitant CNS depressants and alcohol; avoid use<\/li><li>elderly or debilitated patients<\/li><li>elevated intracranial pressure<\/li><li>head injuries<\/li><li>hemostatic defects, underlying<\/li><li>hepatic impairment, severe; monitoring recommended<\/li><li>hypothyroidism<\/li><li>mental impairment and\/or compromised physical abilities; avoid potentially hazardous tasks such as driving a car or operating machinery<\/li><li>prostatic hypertrophy<\/li><li>renal impairment, severe; monitoring recommended<\/li><li>urethral strictures<\/li><\/ul>"},{"id":"20y9s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"20y9s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"20y9s4","title":"Drug Interactions","sub":[{"id":"20y9s4b13","title":"Contraindicated","mono":"<ul><li>Influenza Virus Vaccine, Live (theoretical)<\/li><li>Ketorolac (theoretical)<\/li><li>Riociguat (theoretical)<\/li><\/ul>"},{"id":"20y9s4b14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Adinazolam (probable)<\/li><li>Alfentanil (theoretical)<\/li><li>Alipogene Tiparvovec (theoretical)<\/li><li>Alprazolam (probable)<\/li><li>Alteplase, Recombinant (theoretical)<\/li><li>Amobarbital (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Anileridine (probable)<\/li><li>Anisindione (established)<\/li><li>Apixaban (theoretical)<\/li><li>Aprobarbital (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Argatroban (theoretical)<\/li><li>Beta Glucan (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Bromazepam (probable)<\/li><li>Brotizolam (probable)<\/li><li>Butabarbital (theoretical)<\/li><li>Carisoprodol (theoretical)<\/li><li>Certoparin (probable)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chlordiazepoxide (probable)<\/li><li>Chlorzoxazone (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clobazam (probable)<\/li><li>Clonazepam (probable)<\/li><li>Clopidogrel (theoretical)<\/li><li>Clorazepate (probable)<\/li><li>Clovoxamine (probable)<\/li><li>Cobicistat (theoretical)<\/li><li>Codeine (probable)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (theoretical)<\/li><li>Dantrolene (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Desvenlafaxine (probable)<\/li><li>Diazepam (probable)<\/li><li>Dicumarol (probable)<\/li><li>Dipyridamole (theoretical)<\/li><li>Dipyrone (established)<\/li><li>Donepezil (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Elvitegravir (theoretical)<\/li><li>Enoxaparin (probable)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Estazolam (probable)<\/li><li>Ethchlorvynol (theoretical)<\/li><li>Femoxetine (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Feverfew (theoretical)<\/li><li>Flesinoxan (probable)<\/li><li>Flufenamic Acid (theoretical)<\/li><li>Flunitrazepam (probable)<\/li><li>Fluoxetine (probable)<\/li><li>Flurazepam (probable)<\/li><li>Fluvoxamine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (theoretical)<\/li><li>Halazepam (probable)<\/li><li>Heparin (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Hydromorphone (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketazolam (probable)<\/li><li>Ketoprofen (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Levorphanol (probable)<\/li><li>Lorazepam (probable)<\/li><li>Lormetazepam (probable)<\/li><li>Medazepam (probable)<\/li><li>Mefenamic Acid (theoretical)<\/li><li>Meperidine (probable)<\/li><li>Mephenesin (theoretical)<\/li><li>Mephobarbital (theoretical)<\/li><li>Meprobamate (theoretical)<\/li><li>Metaxalone (theoretical)<\/li><li>Methocarbamol (theoretical)<\/li><li>Methohexital (theoretical)<\/li><li>Methotrexate (probable)<\/li><li>Midazolam (probable)<\/li><li>Milnacipran (probable)<\/li><li>Morphine (probable)<\/li><li>Morphine Sulfate Liposome (probable)<\/li><li>Nadroparin (probable)<\/li><li>Naloxegol (theoretical)<\/li><li>Naproxen (theoretical)<\/li><li>Nefazodone (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nitrazepam (probable)<\/li><li>Nordazepam (probable)<\/li><li>Oxazepam (probable)<\/li><li>Oxymorphone (probable)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Pemetrexed (theoretical)<\/li><li>Pentobarbital (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Pentoxifylline (theoretical)<\/li><li>Phenindione (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenprocoumon (probable)<\/li><li>Piperaquine (theoretical)<\/li><li>Piroxicam (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pralatrexate (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Prazepam (probable)<\/li><li>Primidone (theoretical)<\/li><li>Propoxyphene (probable)<\/li><li>Propyphenazone (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Quazepam (probable)<\/li><li>Remifentanil (probable)<\/li><li>Reteplase, Recombinant (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Secobarbital (theoretical)<\/li><li>Sertraline (probable)<\/li><li>Sibutramine (theoretical)<\/li><li>Sodium Oxybate (theoretical)<\/li><li>Sufentanil (probable)<\/li><li>Sulindac (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Temazepam (probable)<\/li><li>Thiopental (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Ticlopidine (probable)<\/li><li>Tinzaparin (probable)<\/li><li>Tirofiban (probable)<\/li><li>Treprostinil (theoretical)<\/li><li>Triazolam (probable)<\/li><li>Ulipristal (theoretical)<\/li><li>Varicella Virus Vaccine (probable)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Warfarin (theoretical)<\/li><li>Zimeldine (probable)<\/li><\/ul>"},{"id":"20y9s4b15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Alprenolol (probable)<\/li><li>Amiloride (probable)<\/li><li>Amlodipine (probable)<\/li><li>Arotinolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Azilsartan (probable)<\/li><li>Azilsartan Medoxomil (probable)<\/li><li>Azosemide (probable)<\/li><li>Befunolol (probable)<\/li><li>Bemetizide (probable)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Bepridil (probable)<\/li><li>Betamethasone (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bopindolol (probable)<\/li><li>Bucindolol (probable)<\/li><li>Bumetanide (probable)<\/li><li>Bupranolol (probable)<\/li><li>Buthiazide (probable)<\/li><li>Candesartan Cilexetil (probable)<\/li><li>Cannabis (probable)<\/li><li>Canrenoate (probable)<\/li><li>Captopril (established)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celecoxib (probable)<\/li><li>Celiprolol (probable)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Clopamide (probable)<\/li><li>Cortisone (probable)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Deflazacort (probable)<\/li><li>Delapril (established)<\/li><li>Dexamethasone (probable)<\/li><li>Dilevalol (probable)<\/li><li>Diltiazem (probable)<\/li><li>Enalaprilat (established)<\/li><li>Enalapril Maleate (established)<\/li><li>Eprosartan (probable)<\/li><li>Esmolol (probable)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Felodipine (probable)<\/li><li>Flunarizine (probable)<\/li><li>Furosemide (probable)<\/li><li>Gallopamil (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Imidapril (established)<\/li><li>Imipramine (probable)<\/li><li>Indapamide (probable)<\/li><li>Irbesartan (probable)<\/li><li>Isradipine (probable)<\/li><li>Labetalol (probable)<\/li><li>Lacidipine (probable)<\/li><li>Landiolol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Lidoflazine (probable)<\/li><li>Lisinopril (probable)<\/li><li>Losartan (probable)<\/li><li>Manidipine (probable)<\/li><li>Mepindolol (probable)<\/li><li>Methyclothiazide (probable)<\/li><li>Methylprednisolone (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metolazone (probable)<\/li><li>Metoprolol (probable)<\/li><li>Nadolol (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nipradilol (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Nitroglycerin (probable)<\/li><li>Olmesartan Medoxomil (probable)<\/li><li>Ospemifene (established)<\/li><li>Oxprenolol (probable)<\/li><li>Paramethasone (probable)<\/li><li>Penbutolol (probable)<\/li><li>Pindolol (probable)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Prednisolone (probable)<\/li><li>Prednisone (probable)<\/li><li>Probenecid (probable)<\/li><li>Propranolol (probable)<\/li><li>Repaglinide (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Sotalol (probable)<\/li><li>Spironolactone (probable)<\/li><li>Streptokinase (established)<\/li><li>Talinolol (probable)<\/li><li>Tamarind (probable)<\/li><li>Tasosartan (probable)<\/li><li>Telmisartan (probable)<\/li><li>Temocapril (established)<\/li><li>Tenecteplase (probable)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Torsemide (probable)<\/li><li>Triamcinolone (probable)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Valproic Acid (probable)<\/li><li>Valsartan (probable)<\/li><li>Verapamil (probable)<\/li><li>Xipamide (probable)<\/li><\/ul>"}]},"5":{"id":"20y9s5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Neurologic:<\/b>Dizziness, Somnolence<br\/><b>Serious<\/b><br\/><b>Dermatologic:<\/b>Erythema multiforme, Toxic epidermal necrolysis due to drug<br\/>"},"6":{"id":"20y9s6","title":"Drug Name Info","sub":{"0":{"id":"20y9s6b17","title":"US Trade Names","mono":"<ul><li>Fiorinal<\/li><li>Fortabs<\/li><li>Laniroif<\/li><\/ul>"},"2":{"id":"20y9s6b19","title":"Class","mono":"<ul><li>Barbiturate<\/li><li>Butalbital\/Salicylate, Aspirin Combination<\/li><li>Methylxanthine<\/li><li>NSAID<\/li><li>Salicylate, Aspirin<\/li><\/ul>"},"3":{"id":"20y9s6b20","title":"Regulatory Status","mono":"Schedule III<br\/>"},"4":{"id":"20y9s6b21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"20y9s7","title":"Mechanism Of Action","mono":"Aspirin, which hydrolyzes mainly to salicylic acid, provides analgesia while butalbital has anxiolytic and muscle relaxant properties. These two drugs with the addition of caffeine are used to treat the symptoms of tension headache including headache pain, psychic tension, and muscle tension in the head, neck, and shoulder region.<br\/>"},"8":{"id":"20y9s8","title":"Pharmacokinetics","sub":[{"id":"20y9s8b23","title":"Absorption","mono":"<ul><li>Aspirin, Tmax, Oral: 40 minutes<\/li><li>Aspirin, Bioavailability, Oral: variable<\/li><li>Butalbital, Tmax, Oral: 1.5 hours<\/li><li>Butalbital, Bioavailability, Oral: well absorbed<\/li><li>Caffeine, Tmax, Oral: less than 1 hour<\/li><li>Caffeine, Bioavailability, Oral: rapid<\/li><\/ul>"},{"id":"20y9s8b24","title":"Distribution","mono":"<ul><li>Butalbital, Protein binding: 45% (in vitro)<\/li><li>Salicylic acid (from the hydrolysis of aspirin), Protein binding: about 50% to 80%<\/li><\/ul>"},{"id":"20y9s8b25","title":"Metabolism","mono":"<ul><li>Aspirin, Hepatic: extensive via hydrolysis and biotransformation<\/li><li>Aspirin, salicylic acid: active<\/li><li>Aspirin, salicyluric acid, salicyl phenolic glucuronides, salicyl acyl glucuronides, gentisic acid and gentisuric acid: unknown if active or inactive; major<\/li><li>Butalbital, Site of metabolism unknown: 32% of excretion products was conjugated<\/li><li>Butalbital, 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid: unknown if active or inactive; major<\/li><li>Butalbital, 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid: unknown if active or inactive; major<\/li><li>Caffeine, Hepatic: extensive via the hepatic cytochrome P4501A2 (CYP1A2) enzyme subsystem<\/li><li>Caffeine, paraxanthine: active<\/li><li>Caffeine, theobromine: active<\/li><li>Caffeine, theophylline: active<\/li><\/ul>"},{"id":"20y9s8b26","title":"Excretion","mono":"<ul><li>Aspirin, Renal: primarily as metabolites<\/li><li>Butalbital, Renal: 59% to 88% as unchanged drug or metabolites, 32% as conjugated, about 3.6% as unchanged<\/li><li>Caffeine, Renal: 70% changed, 3% unchanged<\/li><\/ul>"},{"id":"20y9s8b27","title":"Elimination Half Life","mono":"<ul><li>Aspirin: about 12 minutes<\/li><li>Butalbital: 35 hours<\/li><li>Caffeine: about 3 hours<\/li><li>Salicylic acid (from aspirin): 3 hours<\/li><\/ul>"}]},"10":{"id":"20y9s10","title":"Monitoring","mono":"<ul><li>pain reduction, improvement in headache<\/li><li>mental and respiratory status<\/li><li>bowel movements<\/li><li>renal function; in patients with preexisting renal disease<\/li><li>liver function tests; in patients with preexisting hepatic disease<\/li><li>CBC, fecal occult blood test; consider with long term use<\/li><li>signs and symptoms of withdrawal<\/li><\/ul>"},"11":{"id":"20y9s11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Capsule: (Aspirin - Butalbital - Caffeine) 325 MG-50 MG-40 MG<\/li><li>Oral Tablet: (Aspirin - Butalbital - Caffeine) 325 MG-50 MG-40 MG<\/li><\/ul><\/li><li><b>Fiorinal<\/b><br\/><ul><li>Oral Capsule: (Aspirin - Butalbital - Caffeine) 325 MG-50 MG-40 MG<\/li><li>Oral Tablet: (Aspirin - Butalbital - Caffeine) 325 MG-50 MG-40 MG<\/li><\/ul><\/li><\/ul>"},"12":{"id":"20y9s12","title":"Toxicology","sub":[{"id":"20y9s12b31","title":"Clinical Effects","mono":"<ul><li><b>ANALEPTICS<\/b><br\/>USES: Analeptics are CNS stimulants. Currently, doxapram is the only analeptic available in the US; however, other analeptic agents that may still be used in other countries include nikethamide, pentylenetetrazol, and bemegride. Historically, these medications have been used to increase minute ventilation and decrease CNS depression. They have also been used for cardiovascular stimulant effects, to induce seizures during EEG monitoring, and for behavioral control in geriatric patients. Doxapram was also used to treat pediatric apnea. Currently, these medications are not commonly used and are not typically recommended for these conditions. Methylphenidate and amphetamine are covered in separate managements. PHARMACOLOGY: Analeptics cause increased pulmonary ventilation by increasing the depth and rate of respiration; they may act by directly stimulating the respiratory center in the medulla or indirectly affecting the carotid body. TOXICOLOGY: Analeptic toxicity is typically an extension of the therapeutic effects due to overstimulation of the CNS, overstimulation of the respiratory drive, and overstimulation of the cardiovascular system. EPIDEMIOLOGY: Analeptic use and overdose are extremely rare. OVERDOSE: Overdose data are limited. It is anticipated that overdose effects may be an extension of events reported with therapeutic use. Early signs of overdose may be excessive pressor effects, such as hypertension, tachycardia, skeletal muscle hyperactivity, and enhanced deep tendon reflexes. Nausea, agitation, confusion, sweating, cough, dyspnea, seizures may also occur. ADVERSE EFFECTS: The following adverse effects have been reported following therapeutic doses of doxapram: Nausea, vomiting, flushing, sweating, pruritus, paresthesia, diarrhea, urinary retention, elevation of BUN, albuminuria, pyrexia, apprehension, disorientation, pupillary dilatation, hallucinations, headache, dizziness, hyperactivity, involuntary movements, muscle spasticity, muscle fasciculations, increases deep tendon reflexes, clonus, seizures, dyspnea, cough, hyperventilation, tachypnea, laryngospasm, bronchospasm, rebound hypoventilation, phlebitis, variations in heart rate, dysrhythmias (including ventricular tachycardia and ventricular fibrillation), chest pain, mild to moderate hypertension, hemolysis with rapid infusion, a decrease in hemoglobin, hematocrit, or red blood cell count. Rarely, analeptics may precipitate an attack of acute porphyria, and may be associated with worsened leukopenia and anemia in patients with preexisting leukopenia or anemia.<br\/><\/li><li><b>CAFFEINE <\/b><br\/>USES: Caffeine (1,3,7-trimethylxanthine) is present in coffee, tea, colas, and chocolate. It is also utilized in over-the-counter cough and cold therapies, and in many dietary supplement products used as anorexiants, diuretics, and stimulants. Botanical sources of caffeine include guarana, yerba mate, and kola nuts. Caffeine is used medicinally for neonatal apnea and postlumbar puncture headache. PHARMACOLOGY: Caffeine is a trimethylxanthine closely related to theophylline. It acts through nonselective inhibition of adenosine receptors and phosphodiesterase. There is also beta-1 and beta-2 adrenergic stimulation secondary to catecholamine release. TOXICOLOGY: Caffeine is an adenosine analog and functions primarily as an adenosine antagonist lowering the seizure threshold. It also inhibits phosphodiesterase, resulting in accumulation of cAMP and calcium, causing organ-specific downstream effects such as smooth muscle relaxation, or muscle\/cardiac\/CNS excitation. Caffeine overdoses result in surges in circulating catecholamines and rennin, as well as increased levels of norepinephrine, dopamine, and serotonin in the brain. EPIDEMIOLOGY: Caffeine is commonly used; however, severe manifestations of toxicity are rare, and most exposures result in mild toxicity. MILD TO MODERATE TOXICITY: The earliest symptoms of acute caffeine poisoning include anorexia, tremor, and restlessness, followed by nausea, vomiting, and tachycardia. Chronic high-dose caffeine intake can lead to &quot;caffeinism,&quot; which includes nervousness, twitching, anxiety, tremulousness, insomnia, palpitations, and hyperreflexia. SEVERE TOXICITY: With serious ingestions, hypokalemia, hyperglycemia, metabolic acidosis, rhabdomyolysis, hypotension, confusion, seizures, tachycardia, and nonfatal dysrhythmias may occur.<br\/><\/li><li><b>SALICYLATES<\/b><br\/>USES: Salicylates are used primarily as an analgesic, antipyretic, anti-inflammatory, and antiplatelet agent. Found in many over-the-counter preparations in oral and topical forms. It may also be found in combination with other agents such as narcotics, barbiturates, and caffeine. Topical forms are often used as rubefacients. Also found in some essential oils in high concentrations such as oil of wintergreen. PHARMACOLOGY: Salicylates inhibit cyclooxygenase, thereby reducing the formation of prostaglandins, and cause platelet dysfunction. TOXICOLOGY: Salicylates stimulate the respiratory center in the brainstem, interfere with the Krebs cycle (limiting ATP production), uncouple oxidative phosphorylation (causing accumulation of pyruvic and lactic acid and heat production), and increase fatty acid metabolism (generating ketone bodies). The net result is a mixed respiratory alkalosis and metabolic acidosis. EPIDEMIOLOGY: Common poisoning which can result in significant morbidity and mortality. MILD TO MODERATE TOXICITY: GI upset, tinnitus, tachypnea, and respiratory alkalosis. SEVERE TOXICITY: Metabolic acidosis, hyperpnea, diaphoresis, fever, altered mental status, seizures, coma, cerebral edema, pulmonary edema and death. Chronic overdoses present more insidiously and may be subtle, especially in the elderly, and may consist primarily of neurologic manifestations such as confusion, delirium, and agitation. Coagulopathy, hepatic injury, and dysrhythmias are rare complications of severe overdose. ADVERSE EFFECTS: GI upset and tinnitus.<br\/><\/li><\/ul>"},{"id":"20y9s12b32","title":"Treatment","mono":"<ul><li><b>ANALEPTICS<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Treatment of mild to moderate toxicity consists of predominantly symptomatic and supportive care. MANAGEMENT OF SEVERE TOXICITY: Patients with severe toxicity may require benzodiazepines or barbiturates for control of agitation or seizures or treatment of rigidity. Treat hyperthermia with benzodiazepines to control agitation and rigidity and external cooling measures. Tachycardia and hypertension generally respond to benzodiazepine sedation. Rarely, patients may require intubation for pulmonary edema.<\/li><li>Decontamination: Acute toxicity is extremely rare as these agents are rarely used. Gastrointestinal decontamination is generally not necessary. Activated charcoal is not recommended due to the risk of seizures and associated aspiration.<\/li><li>Airway management: Patients who develop seizures, pulmonary edema, or respiratory depression may require intubation for airway management.<\/li><li>Antidote: None<\/li><li>Monitoring of patient: Monitor vital signs and mental status. Serum concentrations of these agents are not widely available or useful to guide therapy. Monitor serum electrolytes and creatine kinase in patients with seizures, rigidity, or hyperthermia. All patients with suspected analeptic toxicity should have an ECG. Institute continuous cardiac monitoring in patients with significant tachycardia or an abnormal ECG.<\/li><li>Enhanced elimination procedure: Hemodialysis has not been studied and is unlikely to be of benefit following analeptic toxicity or overdose.<\/li><li>Patient disposition: HOME CRITERIA: There is no role for home management. OBSERVATION CRITERIA: Patients should be observed for 6 hours after exposure. ADMISSION CRITERIA: Patients who develop severe signs and symptoms of analeptic toxicity such as seizures, heart block, marked tachycardia, pulmonary edema, or severe hypertension should be admitted to the hospital. Any patient with recurrent seizures, status epilepticus, recurrent dysrhythmias, or requiring intubation should be admitted to an ICU. CONSULT CRITERIA: Consult a poison center or medical toxicologist for any patient with suspected significant analeptic toxicity.<\/li><\/ul><\/li><li><b>CAFFEINE <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Mild to moderate exposures usually respond to fluid repletion and antiemetic therapy. Electrolyte replacement should be performed as indicated. MANAGEMENT OF SEVERE TOXICITY: There is potential for seizures, vomiting, and dysrhythmias, so consider early airway management. Monitor ECG and vital signs for at least 6 hours after any concerning oral ingestion. Treat agitation and seizures with benzodiazepines. If unsuccessful, phenobarbital or propofol may be utilized. Follow patients for hyperthermia or rhabdomyolysis. Treat hypotension with IV fluid boluses and vasopressin or phenylephrine if hypotension persists; drugs with significant beta-adrenergic effects should be avoided. Hypokalemia usually resolves without aggressive treatment because it is due to an intracellular shift of potassium ions; however, severe hypokalemia should be treated. Beta-blockers effectively reverse cardiotoxic effects mediated by beta-adrenergic stimulation. Treat severe tachyarrhythmias with hypotension not responsive to fluid boluses or pressors with esmolol 50 to 200 mcg\/kg\/min beginning with low doses and titrating to effect. Follow advanced cardiac life support (ACLS) and pediatric advanced life support (PALS) guidelines for malignant dysrhythmias.<\/li><li>Decontamination: PRE-HOSPITAL: Decontamination should be avoided. Mild exposures do not require treatment, and severe overdose can result in seizures and aspiration. HOSPITAL: Activated charcoal adsorbs caffeine effectively. Administration of activated charcoal should be considered on an individual basis; it should be reserved for patients with the potential for significant toxicity and a recent ingestion who are alert or in whom the airway is protected. Gastric lavage is rarely utilized, but might be considered in the rare patient with a recent, life threatening ingestion.<\/li><li>Airway management: As seizures and vomiting are common after severe overdose, it is important to manage the airway early.<\/li><li>Antidote: There is no antidote for caffeine.<\/li><li>Monitoring of patient: No studies are needed in patients with minimal symptoms. Patients with mild to moderate symptoms should have electrolytes checked, and if there is any concern for rhabdomyolysis, a CPK should be checked. An ECG should be performed with continuous cardiac monitoring in moderate to severe poisoning. Caffeine levels are obtainable, but not routinely available in general hospital laboratories and not useful to guide therapy. Serum concentrations greater than 80 mg\/L have been associated with mortality.<\/li><li>Enhanced elimination procedure: Hemodialysis is effective and indicated in patients with severe toxicity (eg, seizures, ventricular dysrhythmias or hypotension).<\/li><li>Patient disposition: HOME CRITERIA: Patients with nontoxic ingestions with minimal symptoms can be managed at home. OBSERVATION CRITERIA: Intentional self-harm attempts should be referred to a health care facility. Observe all patients with mild symptoms (ie, nausea, vomiting, and palpitations) until resolution of symptoms. ADMISSION CRITERIA: Patients with moderate symptoms including palpitations and mild electrolyte disturbances can be observed on telemetry. Any patient showing signs of severe toxicity (ie, seizures, ventricular dysrhythmias or hypotension) should be admitted to the ICU. CONSULT CRITERIA: Involve a poison center or toxicologist with any questions, concerns, or cases of moderate to severe toxicity. If you are considering dialysis, a nephrologist should be involved.<\/li><\/ul><\/li><li><b>SALICYLATES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: An initial salicylate level should be obtained and repeated every 1 to 2 hours until a clear peak and decline is observed. Start intravenous fluids. Concentrations greater than 30 mg\/dL and rising should be treated with urine alkalinization. The presence of a large anion gap metabolic acidosis or altered mental status indicates a more severe poisoning. MANAGEMENT OF SEVERE TOXICITY: Patients with severe poisoning should be continued on urine alkalinization; hemodialysis should be strongly considered. Relative indications for hemodialysis include: renal failure, congestive heart failure, altered mental status, seizures, evidence of cerebral edema, worsening acidosis despite adequate resuscitation, persistently rising salicylate concentrations despite adequate treatment (greater than 50 to 60 mg\/dL in a chronic poisoning or levels greater than 90 to 100 mg\/dL in an acute overdose). Patients with an altered mental status may have cerebral edema; a head CT should be obtained. Mannitol can be given for cerebral edema. Severely ill patients may require respiratory support and intubation. Maintain preintubation minute ventilation at the same high respiratory rate because once the patient's respiratory drive is removed metabolic acidosis may worsen.<\/li><li>Decontamination: PREHOSPITAL: Prehospital decontamination with activated charcoal can be considered for large ingestions in patients with normal mental status in whom there will be a delay to definitive healthcare, but a poison center should be consulted first. HOSPITAL: Activated charcoal should be administered to any patient who presents within 2 hours of a significant ingestion, can adequately protect their airway, and has no alteration in mental status. Administer activated charcoal to patients with large ingestions who present after 2 hours, as salicylate absorption can be delayed and erratic. Consider the use of gastric lavage for patients that present with large ingestions within 2 hours.<\/li><li>Airway management: Patients who are comatose or with altered mental status may need mechanical respiratory support and orotracheal intubation. If the patient requires intubation, monitor end tidal CO2 and arterial blood gases frequently and maintain the preintubation minute ventilation to prevent severe acidosis.<\/li><li>Antidote: There is no specific antidote.<\/li><li>Monitoring of patient: Obtain serial salicylate levels every 1 to 2 hours until concentrations have peaked and are declining; basic metabolic panel every 2 hours until clinical improvement; arterial or venous blood gas for patients undergoing urinary alkalinization or moderate\/severe toxicity. In addition, obtain CBC, liver enzymes, renal function studies, INR and PTT in patients with clinical evidence of moderate\/severe toxicity.<\/li><li>Fluid\/electrolyte balance regulation: Correct dehydration with 0.9% saline 10 to 20 mL\/kg\/hour over 1 to 2 hours until a good urine flow is obtained (at least 3 to 6 mL\/kg\/hour).  In patients in whom urinary alkalinization is being considered, initial hydration may be with 10 to 20 mL\/kg of D5W with 88 to 132 mEq of bicarbonate added.  Patients in shock may require more rapid fluid administration. Correct hypokalemia with intravenous potassium boluses and oral potassium. Monitor urine output and pH hourly.<\/li><li>Acidosis: Administer 1 to 2 mEq\/kg NaHCO3 by IV bolus and begin urinary alkalinization.  Monitor blood gases and urinary pH to guide frequency and quantity of administration. Patients with refractory acidosis, inability to maintain appropriate respiratory alkalosis, or acidemia should be treated with hemodialysis.<\/li><li>Alkaline diuresis: Urinary alkalization will increase elimination of salicylates. Place 150 mEq (3 ampules) of NaHCO3 in 1 liter of 5% dextrose to provide an isotonic solution; administer 10 to 20 mL\/kg initially as a bolus, then infuse at 2 to 3 mL\/kg\/hour. Administer 20 to 40 mEq\/L of potassium chloride as an IV infusion as needed to maintain normokalemia. Oral potassium may be administered if tolerated. Hypokalemia and hypocalcemia may occur with alkalinization and hypokalemia can prevent the development of an alkaline urine. Monitor serum electrolytes (in particular potassium and calcium), serum and urinary pH frequently (every 1 to 2 hours); goal of therapy is a urine pH of 7.5 to 8.<\/li><li>Hemodialysis: Hemodialysis efficiently removes salicylate and corrects acid base and electrolyte abnormalities. Hemodialysis is recommended in patients with high serum salicylate levels (greater than 90 to 100 mg\/dL after acute overdose, to 50 to 60 mg\/dL with chronic intoxication), refractory acidosis, inability to maintain appropriate respiratory alkalosis, acidemia, evidence of CNS toxicity (i.e., seizures, mental status depression, persistent confusion, coma, and cerebral edema), progressive clinical deterioration despite appropriate fluid therapy and attempted urinary alkalinization, acute lung injury, inability to tolerate sodium bicarbonate (e.g., renal insufficiency, pulmonary edema), refractory\/profound electrolyte disturbances, or renal failure. The clinical condition of the patient is more important than the serum salicylate concentration in determining the need for hemodialysis, especially in patients with chronic toxicity or delayed presentation after acute overdose. In patients with early presentation after acute overdose, serum concentrations approaching 100 mg\/dL warrant consideration for dialysis even with mild or moderate clinical manifestations of toxicity. Administer a second dose of activated charcoal to patients with persistently rising salicylate levels despite urinary alkalinization and an initial dose of activated charcoal. Consider whole bowel irrigation with polyethylene glycol for patients with large ingestions of enteric coated products if they are alert and able to protect the airway.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions of less than 150 mg\/kg or 6.5 g, whichever is less, of aspirin equivalent doses can generally be observed at home with normal follow-up procedures. Consider follow-up at periodic intervals of approximately 12 hours after acute ingestion of non-enteric coated salicylate products or 24-hours for enteric-coated aspirin. ADMISSION CRITERIA: Patients who have a rising salicylate concentration, metabolic acidosis, or alterations in mental status should be admitted to an intensive care setting. OBSERVATION CRITERIA: Patients with intentional ingestions and those with unintentional ingestions greater than 150 mg\/kg or 6.5 g of aspirin equivalent doses, whichever is less, should be evaluated in a healthcare facility. For oil of wintergreen (98% methylsalicylate), greater than a lick or taste by children under 6 years of age or greater than 4 mL by patients 6 years of age and older requires referral to an emergency department for evaluation. Patients who have a well defined peak and decline in salicylate concentration and mild to moderate symptoms that resolve with treatment can often be treated and released from an ED observation unit. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing severe poisonings and for recommendations on determining the need for hemodialysis. Women in the third trimester of pregnancy who do not require referral to a healthcare facility for other reasons (ie ingested dose or symptoms) should be referred to an obstetrician for outpatient follow up and assessment of maternal fetal risk.<\/li><\/ul><\/li><\/ul>"},{"id":"20y9s12b33","title":"Range of Toxicity","mono":"<ul><li><b>ANALEPTICS<\/b><br\/>TOXICITY: A preterm infant (born at 28 weeks gestation) inadvertently received a doxapram infusion of 9.5 mg\/kg\/hour, instead of 0.95 mg\/kg\/hour, for approximately 4.5 hours (total dose 72.9 mg), and only experienced nausea and increased gastric residuals as a result. For pentylenetetrazol, an adult dose of 10 g was lethal. For humans, the toxic doses of doxapram, nikethamide, and bemegride are poorly described. THERAPEUTIC DOSE: The only analeptic available for therapeutic use at this time in the US is doxapram. DOXAPRAM: Dose is usually 0.5 to 1 mg\/kg as a single IV injection; MAX 2 mg\/kg (3 g\/24 hours). Dose may be repeated as needed at 5-minute intervals or every 1 to 2 hours for drug-induced CNS depression. For COPD associated with acute hypercapnia, 1 to 2 mg\/min IV infusion.<br\/><\/li><li><b>CAFFEINE<\/b><br\/>TOXICITY: ADULT: An estimated lethal dose is 150 to 200 mg\/kg or 10 to 20 g. One gram has produced significant symptoms in an adult. PEDIATRIC: An estimated ingestion of 35 mg\/kg may lead to moderate toxicity in children. Children and neonates can often tolerate higher doses. Neonates have developed seizures after 36 to 136 mg\/kg IV. THERAPEUTIC DOSE: ADULT: 100 to 200 mg orally every 4 hours. For post dural headache caffeine\/sodium benzoate 500 mg IV for 1 to 2 doses. PEDIATRIC: Neonates: Caffeine citrate: For apnea of prematurity: Loading dose: 20 mg\/kg IV over 30 minutes followed 24 hours later by a daily maintenance dose of 5 to 10 mg\/kg orally or intravenously.<br\/><\/li><li><b>SALICYLATES <\/b><br\/>TOXICITY: ACUTE INGESTION: The acute ingestion of less than 150 mg\/kg or 6.5 g of aspirin equivalent, whichever is less, is not expected to cause significant toxicity. For oil of wintergreen (98% methylsalicylate), greater than a lick or taste by children under 6 years of age or greater than 4 mL by patients 6 years of age and older may cause toxicity and requires referral to an emergency department for evaluation. FATALITIES: As little as 5 mL of oil of wintergreen has resulted in pediatric deaths. THERAPEUTIC DOSE: For children an analgesic or antipyretic dose is 10 to 15 mg\/kg; 325 to 650 mg for adults.<br\/><\/li><\/ul>"}]},"13":{"id":"20y9s13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness or somnolence.<\/li><li>This drug may cause flatulence, nausea, or vomiting.<\/li><li>Tell patients to report signs\/symptoms of toxic epidermal necrolysis (widespread peeling\/blistering of skin).<\/li><li>Patient should maintain adequate hydration to prevent constipation while taking this drug.<\/li><li>Advise patients using drug long-term or in large doses to avoid sudden discontinuation, as this may precipitate signs\/symptoms of withdrawal.<\/li><li>Patient should take drug with food or milk to minimize gastric irritation.<\/li><li>Instruct patient to not drink alcohol while taking this drug.<\/li><li>Patient should avoid additional aspirin or aspirin-containing products during drug therapy, unless approved by healthcare professional.<\/li><\/ul>"}}}